| FATE THERAPEUTICS DL-,001 |
| USA |
| Gesundheit |
| US31189P1021 / A1W50M |
| F6T (Frankfurt) / FATE (NASDAQ) |
| FRA:F6T, ETR:F6T, F6T:GR, NASDAQ:FATE |
| - |
| https://fatetherapeutics... |
|
Fate Therapeutics Inc. operates within the biotechnology sector, specializing in the development of programmed cellular immunotherapies for cancer and immune disorders. The company's key focus lies in..
>Volltext.. |
| 147.94 Mio. EUR |
| 31.78 Mio. EUR |
| 6.06 Mio. EUR |
| -123.45 Mio. EUR |
| -132.58 Mio. EUR |
| -1.12 EUR |
| 67.31 Mio. EUR |
| 34.5 Mio. EUR |
| -93.91 Mio. EUR |
| 7.66 |
| -49.64% |
| 16.9% |
| - |
| - |
| - |
| - |
| FATE THERAPEUTICS, FATE THERAPEUTIC |
| 26.02.26 |
|